Prestige Consumer Healthcare (PBH) Other Non-Current Assets (2011 - 2025)
Prestige Consumer Healthcare's (PBH) quarterly Other Non-Current Assets came in at $3.8 million in Q4 2025, down 40.16% year-on-year from $6.3 million in Q4 2024, and up 10.2% quarter-over-quarter from $3.4 million in Q3 2025.
Prestige Consumer Healthcare (PBH) Other Non-Current Assets (2011 - 2025) Analysis & Trends
Prestige Consumer Healthcare's Other Non-Current Assets history runs 15 years deep, the most recent figure standing at $3.8 million for Q4 2025.
- On a quarterly basis, Other Non-Current Assets fell 40.16% year-over-year to $3.8 million in Q4 2025; TTM through Dec 2025 was $3.8 million, a 40.16% decrease from a year earlier, with the FY2025 full-year figure at $3.3 million, down 42.83% from the prior year.
- Other Non-Current Assets climbed to $3.8 million in Q4 2025 per PBH's latest filing, from $3.4 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $6.7 million in Q3 2024 and bottomed at $2.5 million in Q2 2021.
- The 5-year median for Other Non-Current Assets is $3.3 million (2022), against an average of $3.9 million.
- Across the five-year window, Other Non-Current Assets jumped 99.84% in 2023 and plunged 51.48% in 2025, its largest moves.
- Year by year, Other Non-Current Assets stood at $2.9 million in 2021, then increased by 9.13% to $3.2 million in 2022, then soared by 99.84% to $6.3 million in 2023, then grew by 0.57% to $6.3 million in 2024, then plunged by 40.16% to $3.8 million in 2025.
- Per Business Quant, the three latest PBH Other Non-Current Assets figures stand at $3.8 million (Q4 2025), $3.4 million (Q3 2025), and $3.0 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 49.22 Mn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 1.79 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 351.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 491.06 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 233.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.11 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 73.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 295.00 Mn |
| 10 | Prestige Consumer Healthcare | 2.34 Bn | 2.28 Bn | 157.37 Mn | 3.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.79 Mn |
| Sep 30, 2025 | 3.44 Mn |
| Jun 30, 2025 | 3.02 Mn |
| Mar 31, 2025 | 3.27 Mn |
| Dec 31, 2024 | 6.34 Mn |
| Sep 30, 2024 | 6.73 Mn |
| Jun 30, 2024 | 6.23 Mn |
| Mar 31, 2024 | 5.73 Mn |
| Dec 31, 2023 | 6.30 Mn |
| Sep 30, 2023 | 3.86 Mn |
| Jun 30, 2023 | 3.27 Mn |
| Mar 31, 2023 | 3.01 Mn |
| Dec 31, 2022 | 3.15 Mn |
| Sep 30, 2022 | 2.58 Mn |
| Jun 30, 2022 | 2.74 Mn |
| Mar 31, 2022 | 3.27 Mn |
| Dec 31, 2021 | 2.89 Mn |
| Sep 30, 2021 | 2.56 Mn |
| Jun 30, 2021 | 2.52 Mn |
| Mar 31, 2021 | 2.86 Mn |